Clinical Trial: Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07746882) titled 'Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy' on July 31.

Brief Summary: To screen ischemic stroke patients likely to benefit from anticoagulation and compare the effectiveness and safety of anticoagulation versus antiplatelet therapy in preventing recurrent ischemic stroke within 3 months.

Study Start Date: Aug. 15

Study Type: INTERVENTIONAL

Condition: Stroke Acute Ischemic Stroke

Intervention: DRUG: Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran

Rivaroxaban 15mg once daily, or Edoxaban 30mg once daily, or Apixaban 2.5mg twice...